All Press Releases

Utah-based PhotoPharmics Selected as Global Top 50 Startup MedTech Innovations designates PhotoPharmics as one of the industry’s best and brightest startups working to transform patient care through innovation June 24, 2021. Salt Lake City—PhotoPharmics today...

​PhotoPharmics Innovations Address Global Health Inequalities Utah-based Life Sciences Company to Combine Breakthrough Designation and MCIT to Provide At-home Access for the Treatment of Neurodegenerative Diseases April 12, 2021, Salt Lake City, UT -- Innovation not...

Phase 3 Trial Aims to Establish Non-Motor Improvement in Parkinson’s PhotoPharmics and University of Rochester to Collaborate on Stay-At-Home Trial July 14, 2020, Salt Lake City, UT— PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases,...

FDA Grants Breakthrough Designation for Non-Invasive Phototherapy Device in Parkinson’s Disease PhotoPharmics achieves priority designation for innovative PD therapy April 29, 2020, Salt Lake City, UT— PhotoPharmics, a pioneer in specialized phototherapy, today...

View the full release on EIN Newswire Largest Phototherapy Trial for Parkinson’s Disease PhotoPharmics Finalizing Pivotal Phase 3-Equivalent Trial for Improving Overall Function February 10, 2020, Salt Lake City, UT— PhotoPharmics announced today plans to conduct a...

View the full release on BusinessWirePivotal Parkinson’s Disease Clinical Trial Results Released at the International Movement Disorders Society CongressPhotoPharmics Study Reveals Phototherapy Breakthrough October 5, 2018, Hong Kong, China—PhotoPharmics today...

PhotoPharmics Submits FDA Application for Parkinson’s Disease Therapy 510K De Novo Pathway Key to Market Authorization for Company’s Innovative Medical Device July 16, 2018, Salt Lake City, UT— PhotoPharmics announced today that its De Novo request to the FDA has been...

PhotoPharmics Completes Pivotal Phototherapy Clinical Trial for Parkinson’s Disease Double-Blind Trial Demonstrates Safety and Efficacy of Spectramax™ Medical Device February 1, 2018, Salt Lake City, UT—PhotoPharmics completed a multinational double-blind, randomized...